These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 32266390)

  • 21. A second-generation microRNA-based assay for diagnosing tumor tissue origin.
    Meiri E; Mueller WC; Rosenwald S; Zepeniuk M; Klinke E; Edmonston TB; Werner M; Lass U; Barshack I; Feinmesser M; Huszar M; Fogt F; Ashkenazi K; Sanden M; Goren E; Dromi N; Zion O; Burnstein I; Chajut A; Spector Y; Aharonov R
    Oncologist; 2012; 17(6):801-12. PubMed ID: 22618571
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MicroRNA profiling for the identification of cancers with unknown primary tissue-of-origin.
    Ferracin M; Pedriali M; Veronese A; Zagatti B; Gafà R; Magri E; Lunardi M; Munerato G; Querzoli G; Maestri I; Ulazzi L; Nenci I; Croce CM; Lanza G; Querzoli P; Negrini M
    J Pathol; 2011 Sep; 225(1):43-53. PubMed ID: 21630269
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular characterisation and liquid biomarkers in Carcinoma of Unknown Primary (CUP): taking the 'U' out of 'CUP'.
    Conway AM; Mitchell C; Kilgour E; Brady G; Dive C; Cook N
    Br J Cancer; 2019 Jan; 120(2):141-153. PubMed ID: 30580378
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular diagnosis of the tissue of origin in cancer of unknown primary site: useful in patient management.
    Greco FA
    Curr Treat Options Oncol; 2013 Dec; 14(4):634-42. PubMed ID: 23990214
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Complete genomic characterization in patients with cancer of unknown primary origin in routine diagnostics.
    Schipper LJ; Samsom KG; Snaebjornsson P; Battaglia T; Bosch LJW; Lalezari F; Priestley P; Shale C; van den Broek AJ; Jacobs N; Roepman P; van der Hoeven JJM; Steeghs N; Vollebergh MA; Marchetti S; Cuppen E; Meijer GA; Voest EE; Monkhorst K
    ESMO Open; 2022 Dec; 7(6):100611. PubMed ID: 36463731
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis.
    Moran S; Martínez-Cardús A; Sayols S; Musulén E; Balañá C; Estival-Gonzalez A; Moutinho C; Heyn H; Diaz-Lagares A; de Moura MC; Stella GM; Comoglio PM; Ruiz-Miró M; Matias-Guiu X; Pazo-Cid R; Antón A; Lopez-Lopez R; Soler G; Longo F; Guerra I; Fernandez S; Assenov Y; Plass C; Morales R; Carles J; Bowtell D; Mileshkin L; Sia D; Tothill R; Tabernero J; Llovet JM; Esteller M
    Lancet Oncol; 2016 Oct; 17(10):1386-1395. PubMed ID: 27575023
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of tissue of origin in carcinoma of unknown primary with a microarray-based gene expression test.
    Monzon FA; Medeiros F; Lyons-Weiler M; Henner WD
    Diagn Pathol; 2010 Jan; 5():3. PubMed ID: 20205775
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute.
    Hainsworth JD; Rubin MS; Spigel DR; Boccia RV; Raby S; Quinn R; Greco FA
    J Clin Oncol; 2013 Jan; 31(2):217-23. PubMed ID: 23032625
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of Tumor Tissue of Origin with RNA-Seq Data and Using Gradient Boosting Strategy.
    Li R; Liao B; Wang B; Dai C; Liang X; Tian G; Wu F
    Biomed Res Int; 2021; 2021():6653793. PubMed ID: 33681364
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progress in refining the clinical management of cancer of unknown primary in the molecular era.
    Rassy E; Pavlidis N
    Nat Rev Clin Oncol; 2020 Sep; 17(9):541-554. PubMed ID: 32350398
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gene expression profiling in patients with carcinoma of unknown primary site: from translational research to standard of care.
    Hainsworth JD; Greco FA
    Virchows Arch; 2014 Apr; 464(4):393-402. PubMed ID: 24487792
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site.
    Hayashi H; Kurata T; Takiguchi Y; Arai M; Takeda K; Akiyoshi K; Matsumoto K; Onoe T; Mukai H; Matsubara N; Minami H; Toyoda M; Onozawa Y; Ono A; Fujita Y; Sakai K; Koh Y; Takeuchi A; Ohashi Y; Nishio K; Nakagawa K
    J Clin Oncol; 2019 Mar; 37(7):570-579. PubMed ID: 30653423
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integration of RNA-Seq data with heterogeneous microarray data for breast cancer profiling.
    Castillo D; Gálvez JM; Herrera LJ; Román BS; Rojas F; Rojas I
    BMC Bioinformatics; 2017 Nov; 18(1):506. PubMed ID: 29157215
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Validation of a microRNA-based qRT-PCR test for accurate identification of tumor tissue origin.
    Rosenwald S; Gilad S; Benjamin S; Lebanony D; Dromi N; Faerman A; Benjamin H; Tamir R; Ezagouri M; Goren E; Barshack I; Nass D; Tobar A; Feinmesser M; Rosenfeld N; Leizerman I; Ashkenazi K; Spector Y; Chajut A; Aharonov R
    Mod Pathol; 2010 Jun; 23(6):814-23. PubMed ID: 20348879
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm?
    Olivier T; Fernandez E; Labidi-Galy I; Dietrich PY; Rodriguez-Bravo V; Baciarello G; Fizazi K; Patrikidou A
    Cancer Treat Rev; 2021 Jun; 97():102204. PubMed ID: 33866225
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of molecular profiling in the diagnosis and management of metastatic undifferentiated cancer of unknown primary
    Dermawan JK; Rubin BP
    Semin Diagn Pathol; 2021 Nov; 38(6):193-198. PubMed ID: 33309276
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [CUP syndrome: molecular pathogenesis and biology].
    Krämer A; Gattenlöhner S; Neben K
    Pathologe; 2009 Mar; 30(2):117-24. PubMed ID: 19132375
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pan-cancer transcriptome analysis reveals a gene expression signature for the identification of tumor tissue origin.
    Xu Q; Chen J; Ni S; Tan C; Xu M; Dong L; Yuan L; Wang Q; Du X
    Mod Pathol; 2016 Jun; 29(6):546-56. PubMed ID: 26990976
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A molecular approach integrating genomic and DNA methylation profiling for tissue of origin identification in lung-specific cancer of unknown primary.
    Chen K; Zhang F; Yu X; Huang Z; Gong L; Xu Y; Li H; Yu S; Fan Y
    J Transl Med; 2022 Apr; 20(1):158. PubMed ID: 35382836
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The initial CUP situation and CUP syndrome: pathological diagnostics].
    Moll R
    Pathologe; 2009 Dec; 30 Suppl 2():161-7. PubMed ID: 19816686
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.